Activin RIA, also known as ALK2, TSK7L, SKR1, TSRI, and ACTRI, is a glycosylated 65 kDa type I receptor in the TGFβ serine/threonine kinase receptor family. Binding of TGFβ superfamily ligands induces formation of a heterotetrameric complex that contains two chains each of a type I and a type II receptor in multiple combinations. The type II receptors phosphorylate the type I receptors which then phosphorylate and activate Smad signal transduction proteins. Activin RIA functions in a wide variety of growth and differentiation processes including gastrulation, skeletal system development, and cardiac morphogenesis. Mature human Activin RIA consists of a 103 aa extracellular domain (ECD), a 23 aa transmembrane segment, and a 363 aa cytoplasmic region that includes a Gly/Serrich GS box and the kinase domain. Within the ECD, human Activin RIA shares 99% and 94% aa sequence identity with mouse and rat Activin RIA, respectively. It shares 20% 26% aa sequence identity with other human type I receptors Activin RIB, BMPRIA, BMPRIB, and TGFβ RI. BMP signaling through Activin RIA is enhanced by the direct interaction between Activin RIA and RGMB/ DRAGON, a BMP coreceptor that also associates with other type I and type II receptors. Activin RIA can additionally phosphorylate the coreceptor Endoglin and is required for the inhibitory effect of Endoglin on prostate cancer cell motility.
該Anti-Human ALK2 (Activin R1A)的詳細信息查看ReliaTech提供的產(chǎn)品說明書。溶解建議:Centrifuge vial prior to opening. Reconstitute the antibody with 500 μl sterile PBS and the final concentration is 200 μg/ml.